Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One

Aún no traducido Aún no traducido
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2007

Este artículo no está incluido en ninguna revisión sistemática

Este artículo es parte de los siguientes hilos de publicación
  • CARE-MS I [Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One] (17 documentos)
Cargando información sobre las referencias
The purpose of this study was to establish the efficacy and safety of alemtuzumab (Lemtrada™)
as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with
subcutaneous (SC) interferon beta-1a (Rebif®). The study had enrolled participants who had
not previously received MS disease-modifying therapies. Participants had monthly laboratory
tests and comprehensive testing every 3 months.
Epistemonikos ID: 417862379533f17b514615d921e22487caa3adb8
First added on: Aug 10, 2018